Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription


2 Acta Haematol
1 Am J Clin Pathol
4 Ann Hematol
8 Blood
1 Bone Marrow Transplant
1 Cancer Res
1 Exp Hematol
2 Int J Hematol
1 J Biol Chem
1 J Clin Oncol
5 Leuk Lymphoma
11 Leukemia

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Acta Haematol

  1. DENGLER J, Tesch H, Jentsch-Ullrich K, Gerhardt A, et al
    Treatment-free remission in real-world chronic myeloid leukemia patients: Insights from German hematology practices.
    Acta Haematol. 2022 Jul 29. pii: 000525935. doi: 10.1159/000525935.
    PubMed         Abstract available

  2. BERGER T, Shacham Abulafia A, Shimony S, Pasvolsky O, et al
    Prevalence and Clinical Characteristics of Paraproteinemia Associated with Chronic Myeloid Leukemia.
    Acta Haematol. 2022 Jul 29. pii: 000526168. doi: 10.1159/000526168.
    PubMed         Abstract available

    Am J Clin Pathol

  3. KAUMEYER BA, Fidai SS, Thakral B, Wang SA, et al
    GLUT1 Immunohistochemistry Is a Highly Sensitive and Relatively Specific Marker for Erythroid Lineage in Benign and Malignant Hematopoietic Tissues.
    Am J Clin Pathol. 2022;158:228-234.
    PubMed         Abstract available

    Ann Hematol

  4. BOEREKAMPS A, Hamberg P, Libourel EJ
    Discontinuation of azacitidine in acute myeloid leukemia: a feasible option?
    Ann Hematol. 2022 Aug 4. pii: 10.1007/s00277-022-04939.

  5. DONG T, Wu N, Gao H, Liang S, et al
    CD277 agonist enhances the immunogenicity of relapsed/refractory acute myeloid leukemia towards Vdelta2(+) T cell cytotoxicity.
    Ann Hematol. 2022 Aug 3. pii: 10.1007/s00277-022-04930.
    PubMed         Abstract available

  6. AHMED MZ, Venkatadasari I, Dyer S, Wall K, et al
    Clonal evolution in adult TCF3::HLF-positive acute lymphoblastic leukemia undergoing stem cell transplantation.
    Ann Hematol. 2022 Jul 30. pii: 10.1007/s00277-022-04941.

  7. SEVINDIK OG, Mergen M, Mergen S, Mutlu YG, et al
    To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission.
    Ann Hematol. 2022 Jul 29. pii: 10.1007/s00277-022-04938.


  8. BLACK GS, Huang X, Qiao Y, Tarapcsak S, et al
    Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients.
    Blood. 2022;140:401-405.

  9. LU P, Liu Y, Yang J, Zhang X, et al
    Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial.
    Blood. 2022;140:321-334.
    PubMed         Abstract available

  10. HO JG, Schmidt D, Lowinus T, Ryoo J, et al
    Targeting MDM2 enhances anti-leukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation.
    Blood. 2022 Jul 19. pii: 485955. doi: 10.1182/blood.2022016082.
    PubMed         Abstract available

  11. GERDEMANN U, Alvarez-Calderon F
    Uncovering CD4+ T-cell exhaustion in B-ALL.
    Blood. 2022;140:294-296.

  12. VELASQUEZ MP, Mamonkin M
    CD7 CAR: sword and shield.
    Blood. 2022;140:293-294.

  13. CICHOCKI F, Goodridge J, Bjordahl R, Mahmood S, et al
    Dual-antigen targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia.
    Blood. 2022 Aug 2. pii: 486089. doi: 10.1182/blood.2021015184.
    PubMed         Abstract available

  14. IACOBUCCI I, Witkowski MT, Mullighan CG
    Single-cell analysis of acute lymphoblastic and lineage ambiguous leukemia - approaches and molecular insights.
    Blood. 2022 Aug 4. pii: 486119. doi: 10.1182/blood.2022016954.
    PubMed         Abstract available

  15. HANDA S, Lee JO, Derkach A, Stone RM, et al
    Long Term Outcomes in Patients with Relapsed or Refractory Hairy Cell Leukemia Treated with Vemurafenib Monotherapy.
    Blood. 2022 Aug 5. pii: 486128. doi: 10.1182/blood.2022016183.
    PubMed         Abstract available

    Bone Marrow Transplant

  16. EL CHAER F, Ballen KK
    Measurable residual disease for secondary acute myeloid leukemia prior to allogeneic hematopoietic cell transplantation: does it make a difference?
    Bone Marrow Transplant. 2022 Jul 28. pii: 10.1038/s41409-022-01765.

    Cancer Res

  17. HNATIUK AP, Bruyneel AAN, Tailor D, Pandrala M, et al
    Reengineering Ponatinib to Minimize Cardiovascular Toxicity.
    Cancer Res. 2022;82:2777-2791.
    PubMed         Abstract available

    Exp Hematol

  18. LIN C, Xu J, Li N, Li Q, et al
    5-Aza-dC promotes T-cell acute lymphoblastic leukemia cell invasion via downregulation of DNMT1 and upregulation of MMP-2 and MMP-9.
    Exp Hematol. 2022 Jul 28. pii: S0301-472X(22)00579.
    PubMed         Abstract available

    Int J Hematol

  19. HAGINO T, Sato T, Saga R, Hidai H, et al
    Myeloid leukemoid reaction after initial azacitidine therapy for chronic myelomonocytic leukemia.
    Int J Hematol. 2022 Jul 19. pii: 10.1007/s12185-022-03422.
    PubMed         Abstract available

  20. LAGANA A, Scalzulli E, Carmosino I, Martelli M, et al
    Asciminib as a third line option in chronic myeloid leukemia.
    Int J Hematol. 2022 Aug 5. pii: 10.1007/s12185-022-03432.
    PubMed         Abstract available

    J Biol Chem

  21. ZHUANG H, Ren Y, Mao C, Zhong Y, et al
    Induction of zinc finger protein RNF6 auto-ubiquitination for the treatment of myeloma and chronic myeloid leukemia.
    J Biol Chem. 2022 Aug 1:102314. doi: 10.1016/j.jbc.2022.102314.
    PubMed         Abstract available

    J Clin Oncol

  22. SOCIE G
    Long-Term Outcomes After Transplantation for Acute Myelogenous Leukemia.
    J Clin Oncol. 2022 Aug 5:JCO2201177. doi: 10.1200/JCO.22.01177.
    PubMed         Abstract available

    Leuk Lymphoma

  23. SUDUTAN T, Erbilgin Y, Hatirnaz Ng O, Karaman S, et al
    Zinc finger protein 384 (ZNF384) impact on childhood mixed phenotype acute leukemia and B-cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2022 Aug 3:1-9. doi: 10.1080/10428194.2022.2095630.
    PubMed         Abstract available

  24. PERAGINE N, De Propris MS, Intoppa S, Milani ML, et al
    Early CD49d downmodulation in chronic lymphocytic leukemia patients treated front-line with ibrutinib plus rituximab predicts long-term response.
    Leuk Lymphoma. 2022 Aug 1:1-5. doi: 10.1080/10428194.2022.2105324.

  25. TESTI AM, Al-Jadiry MF, Ghali HH, Fadhil SA, et al
    Childhood acute promyelocytic leukemia in a pediatric cancer referral center in Baghdad, Iraq. Improved results with ATRA extended consolidation.
    Leuk Lymphoma. 2022 Aug 1:1-8. doi: 10.1080/10428194.2022.2105328.
    PubMed         Abstract available

    Optimal dosing of cytarabine in childhood acute myeloid leukemia: do we have the answer yet?
    Leuk Lymphoma. 2022 Aug 1:1-3. doi: 10.1080/10428194.2022.2105327.

  27. KUSS B, Nagarajan C, Hsieh WS, Cheah CY, et al
    Practical management of chronic lymphocytic leukemia with acalabrutinib.
    Leuk Lymphoma. 2022 Jul 19:1-10. doi: 10.1080/10428194.2022.2098289.
    PubMed         Abstract available


  28. XIANG P, Yang X, Escano L, Dhillon I, et al
    Elucidating the importance and regulation of key enhancers for human MEIS1 expression.
    Leukemia. 2022;36:1980-1989.
    PubMed         Abstract available

  29. GBADAMOSI MO, Shastri VM, Elsayed AH, Ries R, et al
    A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials.
    Leukemia. 2022;36:2022-2031.
    PubMed         Abstract available

  30. KONGKIATKAMON S, Terkawi L, Guan Y, Adema V, et al
    Rare germline alterations of myeloperoxidase predispose to myeloid neoplasms.
    Leukemia. 2022;36:2086-2096.
    PubMed         Abstract available

  31. MEYER AE, Stelloh C, Pulakanti K, Burns R, et al
    Combinatorial genetics reveals the Dock1-Rac2 axis as a potential target for the treatment of NPM1;Cohesin mutated AML.
    Leukemia. 2022;36:2032-2041.
    PubMed         Abstract available

  32. ROHNERT MA, Kramer M, Schadt J, Ensel P, et al
    Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia.
    Leukemia. 2022 Jul 18. pii: 10.1038/s41375-022-01647.
    PubMed         Abstract available

  33. SCHONFELD L, Rinke J, Hinze A, Nagel SN, et al
    ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia.
    Leukemia. 2022 Jul 28. pii: 10.1038/s41375-022-01648.
    PubMed         Abstract available

  34. ESCUDERO A, Takagi M, Auer F, Friedrich UA, et al
    Clinical and immunophenotypic characteristics of familial leukemia predisposition caused by PAX5 germline variants.
    Leukemia. 2022 Jul 28. pii: 10.1038/s41375-022-01661.

  35. ONG JZL, Yokomori R, Wong RWJ, Tan TK, et al
    Requirement for TP73 and genetic alterations originating from its intragenic super-enhancer in adult T-cell leukemia.
    Leukemia. 2022 Jul 30. pii: 10.1038/s41375-022-01655.
    PubMed         Abstract available

  36. SOVERINI S, De Santis S, Martelli M, Monaldi C, et al
    Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia.
    Leukemia. 2022 Jul 30. pii: 10.1038/s41375-022-01660.
    PubMed         Abstract available

  37. FENG P, Chen D, Wang X, Li Y, et al
    Inhibition of the m(6)A reader IGF2BP2 as a strategy against T-cell acute lymphoblastic leukemia.
    Leukemia. 2022 Aug 1. pii: 10.1038/s41375-022-01651.
    PubMed         Abstract available

  38. JAHN N, Jahn E, Saadati M, Bullinger L, et al
    Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.
    Leukemia. 2022 Aug 3. pii: 10.1038/s41375-022-01650.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.